# A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections

> **NCT00360607** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 307 (actual)

## Conditions studied

- Infection

## Interventions

- **DRUG:** Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.
- **DRUG:** Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited
- **DRUG:** Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.
- **DRUG:** Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.

## Key facts

- **NCT ID:** NCT00360607
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2008-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360607, "A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00360607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*